Clinical remission of CFRD could be explained by the introduction of CFTR modulators at our centre in 2021, which likely improved pulmonary exacerbations and the hyperglycaemia associated with acute disease. The gene discussed is CFTR; the disease is cystic fibrosis-related diabetes.